Everything below concerns NR1D2. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
acquired bowel herniation (this becomes a risk for larger donor sites (>4 cm)). About 20 cases have been reported in the literature from 1945 until 1989 and only a few hundred cases have been reported worldwide meralgia paresthetica (injury to the lateral femoral cutaneous nerve also called Bernhardt-Roth's syndrome) pelvic instability fracture (extremely rare and usually with other factors) injury to the clunial nerves (this will cause posterior pelvic pain which is worsened by sitting) injury to the ilioinguinal nerve infection minor hematoma (a common occurrence) deep hematoma requiring surgical intervention seroma ureteral injury pseudoaneurysm of iliac artery (rare) tumor transplantation cosmetic defects (chiefly caused by not preserving the superior pelvic brim) chronic pain Bone grafts harvested from the posterior iliac crest in general have less morbidity, but depending on the type of surgery, may require a flip while the patient is under general anesthesia.
== Early life and education == Lucy Letby was born on 4 January 1990 in Hereford, the only child of a furniture salesman and an accounts clerk. She attended St. James' Church of England primary school, Aylestone School and Hereford Sixth Form College. According to a friend interviewed by the BBC, she had long expressed an interest in neonatal nursing. Letby studied child nursing at the University of Chester, completing clinical placements at Liverpool Women's Hospital and the Countess of Chester Hospital. During her final year she failed an assessed placement but passed a subsequent retrieval placement after requesting a different assessor. One of her assessors later told the 2024 statutory inquiry that she had considered Letby inexperienced and lacking confidence in some clinical areas. Letby graduated with a Bachelor of Science in Nursing with a speciality in child nursing in September 2011 and completed a further placement at Liverpool Women's Hospital the following year.
Crameri made his AFL debut for Essendon against Collingwood in Round 20 of the 2010 AFL season. Crameri has had a great 2011 season up forward for Essendon, kicking 34 goals and was the club's leading goalkicker. At the Crichton Medal, Essendon FC Best & Fairest, he was awarded the Matthew Lloyd Leading Goal Kicking Award, and was the Essendon Football Club Most Improved player for 2011. For the 2012 season, Crameri has inherited the #12 guernsey formerly worn by Andrew Welsh, who retired at the end of the 2011 season. The Goldfields Region Sports Association awarded Crameri the Jack Worrall Medal for the region's most outstanding sportsperson for 2011. On Thursday 24 October 2013, it was announced that Crameri had been traded from Essendon to the Western Bulldogs in exchange for pick number 26 in the National Draft. Crameri, along with 33 other past and present Essendon players, was found guilty of using a banned performance-enhancing substance, thymosin beta-4, as part of Essendon's sports supplements program during the 2012 season. He and his teammates were initially found not guilty in March 2015 by the AFL Anti-Doping Tribunal, but a guilty verdict was returned in January 2016 after an appeal by the World Anti-Doping Agency. He was suspended for two years which, with backdating, ended in November 2016; as a result, he served approximately fourteen months of his suspension and missed the entire 2016 AFL season, including the Bulldogs' premiership win in October.
The families of two missing people from Trinidad and Tobago identified them publicly and suspected they were killed in the 14 October strike; one family said their relative was a fisherman who traveled often to Venezuela and denied he was involved in trafficking drugs. MSNBC wrote that one had a drug-related charge from 2018, and the other had been released in 2021 after a prison sentence for a 2009 murder. In the Paria Peninsula of Sucre state in Venezuela, from which the first boat struck on 1 September allegedly originated, Venezuelan media reported the area was known for trafficking, although not necessarily by Tren de Aragua, and some family members stated that villagers had become involved in illicit activity out of economic necessity. Inhabitants describing a town in mourning published tributes containing photos of the deceased beginning early on 3 September. The deceased included eight persons from San Juan de Unare and three from a nearby town, Güiria. The New York Times reported that "Venezuelan security officials descended on San Juan de Unare, cut off the electricity and made clear that public pronouncements about the attacks were not welcome, according to four townspeople, including the niece of one of the victims." Associated Press journalist Regina Garcia Cano visited Sucre just after the first Venezuelan strike and interviewed dozens of people; she wrote of the "sources' very real fears of being punished—particularly by the Venezuelan government—for speaking to reporters".
Sources: en.wikipedia.org
== Contraindications == Contraindications of tizanidine include concomitant use with strong CYP1A2 inhibitors and known hypersensitivity to tizanidine or its excipients. Tizanidine is contraindicated with strong CYP1A2 inhibitors as these drugs profoundly increase tizanidine levels. Warnings and precautions for tizanidine include hypotension, liver injury, sedation, and hallucinations and psychotic-like symptoms.
== Research == Enobosarm is currently under development for the treatment of breast cancer. It was also previously under development for a variety of other potential uses, including treatment of cachexia, Duchenne muscular dystrophy, muscle atrophy or sarcopenia, and stress incontinence. However, development for all other indications has been discontinued. Enobosarm was assessed for the treatment of muscle wasting in people with lung cancer in two phase 3 clinical trials. The findings of these trials were reported in 2013. Enobosarm significantly improved lean body mass in the trials, but it was not effective in improving muscle strength, as measured by stair climb power. Consequent to these findings, enobosarm did not gain regulatory approval, and development for this use was terminated. Enobosarm had originally been under development for the treatment of sarcopenia (age-related muscle atrophy). However, the FDA requested a cardiovascular safety study be conducted to proceed with phase 3 trials for this indication. The developer of enobosarm refused to conduct this study due to the considerable costs that would be involved. Instead, it opted to trial enobosarm for muscle wasting in cachexia patients, in whom the FDA was more tolerant to cardiovascular side effects and did not require cardiovascular safety evaluation. Following negative findings for muscle wasting, enobosarm was evaluated for the treatment of stress urinary incontinence in postmenopausal women. It was expected that enobosarm might be effective for this use by strengthening the pelvic floor muscles.
=== Safety of radiolabeled somatostatin receptor antagonists === In general, somatostatin receptor antagonists were noted to be well tolerated. However, due to its mechanism of action, it may decrease the effectiveness of SSA therapy (Somatostatin Analogue Therapy), but other studies indicate SSA may not need to be stopped if somatostatin antagonists are used to for tumor labelling instead of agonists. As somatostatin can cause inhibition of hormone production that uses it as a mediating hormone, it has an antiproliferative effect on cell tumors, especially in neuroendocrine tumors. Somatostatin analogue therapy uses longer-acting agonists than the endogenous somatostatin to extend the antiproliferative effects. Somatostatin receptor antagonists can bind to the receptors without activating them, antagonizing the therapeutic inhibitory effects of SSA therapy. Slow intravenous injection might be used until further safety data become available.
==== SAINT ==== Possibly as a response to the Soviet programme, the United States began Project SAINT, which was intended to provide anti-satellite capability to be used in the case of war with the Soviet Union. However, less is known about the mission profiles of this project compared to the Soviet programme, and the project was cancelled due to budget constraints.
=== Heart and blood vessels === People with RA are more prone to atherosclerosis, and risk of myocardial infarction (heart attack) and stroke is markedly increased. Other possible complications that may arise include: pericarditis, endocarditis, left ventricular failure, valvulitis and fibrosis. Many people with RA do not experience the same chest pain that others feel when they have angina or myocardial infarction. To reduce cardiovascular risk, it is crucial to maintain optimal control of the inflammation caused by RA (which may be involved in causing the cardiovascular risk), and to use exercise and medications appropriately to reduce other cardiovascular risk factors such as blood lipids and blood pressure. Doctors who treat people with RA should be sensitive to cardiovascular risk when prescribing anti-inflammatory medications, and may want to consider prescribing routine use of low doses of aspirin if the gastrointestinal effects are tolerable.
Sources: en.wikipedia.org
=== Acute toxicity === Melamine is reported to have an oral median lethal dose (LD50) of 3248 mg/kg based on rat data. It is also an irritant when inhaled or in contact with the skin or eyes. The reported dermal LD50 is greater than 1000 mg/kg for rabbits. A study by Soviet researchers in the 1980s suggested that melamine cyanurate, commonly used as a fire retardant, could be more toxic than either melamine or cyanuric acid alone. For rats and mice, the reported LD50 for melamine cyanurate was 4.1 g/kg (given inside the stomach) and 3.5 g/kg (via inhalation), compared to 6.0 and 4.3 g/kg for melamine and 7.7 and 3.4 g/kg for cyanuric acid respectively. A toxicology study in animals conducted after recalls of contaminated pet food concluded that the combination of melamine and cyanuric acid in diet does lead to acute kidney injury in cats. A 2008 study produced similar experimental results in rats and characterized the melamine and cyanuric acid in contaminated pet food from the 2007 outbreak. A 2010 study from Lanzhou University attributed kidney failure in humans to uric acid stone accumulation after ingestion of melamine resulting in a rapid aggregation of metabolites such as cyanuric acid diamide (ammeline) and cyanuric acid. A 2013 study demonstrated that melamine can be metabolized to cyanuric acid by gut bacteria. In particular, Klebsiella terrigena was determined to be a factor in melamine toxicity. In culture, K. terrigena was shown to convert melamine to cyanuric acid directly.
The primary use of saffron is in food and drink preparation. Saffron has a long history of use in traditional medicine. Saffron has also been used as a fabric dye, particularly in China and India, and in perfumery. It is used for religious purposes in India. In the European E number categorisation for food elements and additives, Saffron is coded as E164.
=== 21st century === Since 1999, Dairy Farm has continued to expand its footprint by acquiring supermarket and other retail operations in Taiwan, Malaysia, Singapore and Indonesia. Notably, it also acquired IKEA Hong Kong, Taiwan in 2002 and began Ikea's Indonesian operation in 2014. In May 2012, Dairy Farm bought a 50% stake in the Rustan Supercenters, Inc., the Rustan group's supermarket chain. 36% came from the Tantoco family and 14% from the Spinnaker group. Its holdings increased to 64% in 2015 and 100% in 2017. On March 23, 2018, the entire stake was sold to Robinsons Retail Holdings, Inc. through a stock swap, yielding Dairy Farm 18.25% of Robinsons Retail Holdings, Inc. stock. In 2018, therefore, Rustan Supercenters are fully acquired by Robinsons Retail Holdings the 20.00% of which is owned by Mulgrave Corporation and GCH Investments, wholly owned subsidiaries of Dairy Farm. As of June 2011, Dairy Farm is 78% owned by Jardine Matheson Holdings. In August 2021, Dairy Farm rebranded its trading name to DFI Retail Group. On 5 May 2022, the company subsequently changed its legal name to DFI Retail Group Holdings Limited, effectively phased out the Dairy Farm branding.
== Analogs == Growth-hormone-releasing hormone is the lead compound for a number of structural and functional analogs, such as Pro-Pro-hGHRH(1-44)-Gly-Gly-Cys, CJC-1293, and CJC-1295. Many GHRH analogs remain primarily research chemicals, although some have specific applications. Sermorelin, a functional peptide fragment of GHRH, has been used in the diagnosis of deficiencies in growth hormone secretion. Tesamorelin, under the trade name Egrifta, received U.S. Food and Drug Administration approval in 2010 for the treatment of lipodystrophy in HIV patients under highly active antiretroviral therapy, and, in 2011, was investigated for effects on certain cognitive tests in the elderly. As a category, the use of GHRH analogs by professional athletes may be prohibited by restrictions on doping in sport because they act as growth hormone secretagogues.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.